Share Price and Basic Stock Data
Last Updated: March 9, 2025, 8:21 pm
| PEG Ratio | 144.07 |
|---|
Competitors of Astrazeneca Pharma India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| MPS Pharmaa Ltd | 6.71 Cr. | 3.51 | 4.33/3.05 | 0.80 | 0.00 % | 9.15 % | 34.9 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 53.1 Cr. | 71.5 | 94.9/32.1 | 18.0 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 38.0 Cr. | 26.0 | 29.0/8.74 | 38.8 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
| Godavari Drugs Ltd | 70.4 Cr. | 93.5 | 155/79.0 | 11.4 | 55.4 | 0.00 % | 14.4 % | 15.5 % | 10.0 |
| Industry Average | 17,255.37 Cr | 1,081.84 | 42.42 | 185.80 | 0.37% | 16.00% | 16.32% | 6.27 |
Quarterly Result
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 201 | 232 | 232 | 236 | 250 | 285 | 295 | 311 | 306 | 383 | 388 | 408 | 440 |
| Expenses | 186 | 194 | 204 | 195 | 213 | 225 | 228 | 258 | 291 | 334 | 349 | 355 | 363 |
| Operating Profit | 15 | 38 | 28 | 41 | 37 | 60 | 67 | 53 | 15 | 49 | 38 | 53 | 77 |
| OPM % | 7% | 16% | 12% | 17% | 15% | 21% | 23% | 17% | 5% | 13% | 10% | 13% | 17% |
| Other Income | 5 | 4 | 4 | 7 | 7 | -32 | 8 | 25 | 10 | 9 | -49 | 8 | -26 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | 0 | 0 | 0 |
| Depreciation | 4 | 4 | 5 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 9 | 9 |
| Profit before tax | 16 | 37 | 27 | 44 | 39 | 23 | 71 | 73 | 20 | 54 | -15 | 51 | 42 |
| Tax % | 30% | 24% | 26% | 26% | 26% | 26% | 25% | 29% | 23% | 27% | -22% | 25% | 27% |
| Net Profit | 11 | 28 | 20 | 33 | 29 | 17 | 54 | 52 | 16 | 39 | -12 | 38 | 31 |
| EPS in Rs | 4.57 | 11.19 | 8.06 | 13.02 | 11.72 | 6.91 | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 |
Last Updated: March 3, 2025, 5:29 pm
Below is a detailed analysis of the quarterly data for Astrazeneca Pharma India Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is ₹440.00 Cr.. The value appears strong and on an upward trend. It has increased from 408.00 Cr. (Sep 2024) to ₹440.00 Cr., marking an increase of ₹32.00 Cr..
- For Expenses, as of Dec 2024, the value is ₹363.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 355.00 Cr. (Sep 2024) to ₹363.00 Cr., marking an increase of ₹8.00 Cr..
- For Operating Profit, as of Dec 2024, the value is ₹77.00 Cr.. The value appears strong and on an upward trend. It has increased from 53.00 Cr. (Sep 2024) to ₹77.00 Cr., marking an increase of ₹24.00 Cr..
- For OPM %, as of Dec 2024, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 13.00% (Sep 2024) to 17.00%, marking an increase of 4.00%.
- For Other Income, as of Dec 2024, the value is ₹-26.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Sep 2024) to ₹-26.00 Cr., marking a decrease of 34.00 Cr..
- For Interest, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Depreciation, as of Dec 2024, the value is ₹9.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 9.00 Cr..
- For Profit before tax, as of Dec 2024, the value is ₹42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Sep 2024) to ₹42.00 Cr., marking a decrease of 9.00 Cr..
- For Tax %, as of Dec 2024, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Sep 2024) to 27.00%, marking an increase of 2.00%.
- For Net Profit, as of Dec 2024, the value is ₹31.00 Cr.. The value appears to be declining and may need further review. It has decreased from 38.00 Cr. (Sep 2024) to ₹31.00 Cr., marking a decrease of 7.00 Cr..
- For EPS in Rs, as of Dec 2024, the value is 12.34. The value appears to be declining and may need further review. It has decreased from ₹15.37 (Sep 2024) to 12.34, marking a decrease of ₹3.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 7, 2025, 9:11 pm
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 390 | 474 | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,619 |
| Expenses | 459 | 487 | 528 | 547 | 506 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,402 |
| Operating Profit | -68 | -13 | -11 | 16 | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 217 |
| OPM % | -18% | -3% | -2% | 3% | 7% | 8% | 10% | 15% | 17% | 11% | 16% | 14% | 13% |
| Other Income | 10 | 23 | 6 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | -14 | 51 | -58 |
| Interest | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 12 | 10 | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 26 |
| Profit before tax | -70 | -0 | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 132 |
| Tax % | 27% | -0% | 9% | 44% | 41% | 25% | 37% | 27% | 26% | 26% | 26% | ||
| Net Profit | -90 | -1 | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 97 |
| EPS in Rs | -35.81 | -0.20 | -8.34 | 2.10 | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 38.78 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 3% | 5% | 41% | 40% | 37% |
YoY Net Profit Growth
| Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 98.89% | -2000.00% | 123.81% | 300.00% | 30.00% | 107.69% | 33.33% | 29.17% | -33.33% | 59.68% | 63.64% |
| Change in YoY Net Profit Growth (%) | 0.00% | -2098.89% | 2123.81% | 176.19% | -270.00% | 77.69% | -74.36% | -4.17% | -62.50% | 93.01% | 3.96% |
Astrazeneca Pharma India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: November 15, 2024, 1:40 am
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 95 | 167 | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 674 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 9 | 7 | 5 | 17 |
| Other Liabilities | 206 | 244 | 261 | 247 | 193 | 214 | 261 | 330 | 306 | 337 | 389 | 362 | 545 |
| Total Liabilities | 306 | 416 | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,241 |
| Fixed Assets | 25 | 94 | 101 | 97 | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 69 |
| CWIP | 74 | 9 | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 208 | 312 | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,172 |
| Total Assets | 306 | 416 | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,241 |
Below is a detailed analysis of the balance sheet data for Astrazeneca Pharma India Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹5.00 Cr..
- For Reserves, as of Sep 2024, the value is ₹674.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹707.00 Cr. (Mar 2024) to ₹674.00 Cr., marking a decrease of 33.00 Cr..
- For Borrowings, as of Sep 2024, the value is ₹17.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹5.00 Cr. (Mar 2024) to ₹17.00 Cr., marking an increase of 12.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹545.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹362.00 Cr. (Mar 2024) to ₹545.00 Cr., marking an increase of 183.00 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹1,241.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,078.00 Cr. (Mar 2024) to ₹1,241.00 Cr., marking an increase of 163.00 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹69.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹67.00 Cr. (Mar 2024) to ₹69.00 Cr., marking an increase of 2.00 Cr..
- For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
- For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
- For Other Assets, as of Sep 2024, the value is ₹1,172.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,011.00 Cr. (Mar 2024) to ₹1,172.00 Cr., marking an increase of 161.00 Cr..
- For Total Assets, as of Sep 2024, the value is ₹1,241.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,078.00 Cr. (Mar 2024) to ₹1,241.00 Cr., marking an increase of 163.00 Cr..
Notably, the Reserves (₹674.00 Cr.) exceed the Borrowings (17.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -68.00 | -13.00 | -11.00 | 16.00 | 37.00 | 46.00 | 71.00 | 109.00 | 123.00 | 77.00 | 158.00 | 179.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 26 | 41 | 30 | 54 | 29 | 35 | 40 | 37 | 38 | 39 | 39 | 43 |
| Inventory Days | 202 | 210 | 157 | 141 | 121 | 229 | 186 | 197 | 198 | 164 | 193 | 140 |
| Days Payable | 214 | 241 | 203 | 174 | 184 | 257 | 266 | 251 | 221 | 223 | 231 | 121 |
| Cash Conversion Cycle | 14 | 10 | -16 | 21 | -34 | 7 | -39 | -17 | 15 | -20 | 1 | 62 |
| Working Capital Days | -56 | -45 | -15 | -28 | -36 | -8 | -14 | -15 | -15 | -33 | -17 | 20 |
| ROCE % | -53% | -12% | -13% | 4% | 15% | 19% | 27% | 34% | 30% | 16% | 31% | 31% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 645,850 | 0.93 | 427.33 | 645,850 | 2025-03-10 | 0% |
| Nippon India Pharma Fund | 11,561 | 0.11 | 7.65 | 645,850 | 2025-03-10 | -98.21% |
| ICICI Prudential MNC Fund | 5,667 | 0.24 | 3.75 | 645,850 | 2025-03-10 | -99.12% |
| ICICI Prudential S&P BSE 500 ETF | 72 | 0.03 | 0.05 | 645,850 | 2025-03-10 | -99.99% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 64.60 | 39.70 | 24.60 | 37.30 | 28.90 |
| Diluted EPS (Rs.) | 64.60 | 39.70 | 24.60 | 37.30 | 28.90 |
| Cash EPS (Rs.) | 70.58 | 46.22 | 31.42 | 45.37 | 36.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 284.77 | 235.48 | 204.56 | 182.47 | 145.78 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 284.77 | 235.48 | 204.56 | 182.47 | 145.78 |
| Dividend / Share (Rs.) | 24.00 | 16.00 | 10.00 | 2.00 | 1.00 |
| Revenue From Operations / Share (Rs.) | 518.21 | 401.19 | 322.24 | 325.42 | 332.72 |
| PBDIT / Share (Rs.) | 87.70 | 76.49 | 40.38 | 59.32 | 53.48 |
| PBIT / Share (Rs.) | 81.72 | 69.98 | 33.60 | 51.27 | 46.04 |
| PBT / Share (Rs.) | 87.82 | 53.64 | 33.22 | 50.84 | 45.59 |
| Net Profit / Share (Rs.) | 64.60 | 39.72 | 24.64 | 37.32 | 28.88 |
| PBDIT Margin (%) | 16.92 | 19.06 | 12.52 | 18.22 | 16.07 |
| PBIT Margin (%) | 15.77 | 17.44 | 10.42 | 15.75 | 13.83 |
| PBT Margin (%) | 16.94 | 13.37 | 10.30 | 15.62 | 13.70 |
| Net Profit Margin (%) | 12.46 | 9.89 | 7.64 | 11.46 | 8.68 |
| Return on Networth / Equity (%) | 22.68 | 16.86 | 12.04 | 20.45 | 19.81 |
| Return on Capital Employeed (%) | 28.34 | 29.11 | 16.03 | 27.20 | 30.36 |
| Return On Assets (%) | 14.98 | 10.08 | 7.19 | 12.04 | 10.22 |
| Asset Turnover Ratio (%) | 1.26 | 1.09 | 0.98 | 1.10 | 1.31 |
| Current Ratio (X) | 2.61 | 2.18 | 2.12 | 2.04 | 1.66 |
| Quick Ratio (X) | 1.97 | 1.68 | 1.70 | 1.51 | 1.15 |
| Inventory Turnover Ratio (X) | 0.61 | 0.51 | 0.59 | 0.59 | 0.49 |
| Dividend Payout Ratio (NP) (%) | 24.76 | 20.14 | 8.11 | 5.35 | 3.46 |
| Dividend Payout Ratio (CP) (%) | 22.66 | 17.30 | 6.36 | 4.40 | 2.75 |
| Earning Retention Ratio (%) | 75.24 | 79.86 | 91.89 | 94.65 | 96.54 |
| Cash Earning Retention Ratio (%) | 77.34 | 82.70 | 93.64 | 95.60 | 97.25 |
| Interest Coverage Ratio (X) | 182.71 | 303.52 | 106.25 | 136.06 | 117.27 |
| Interest Coverage Ratio (Post Tax) (X) | 121.90 | 222.46 | 65.84 | 86.60 | 64.34 |
| Enterprise Value (Cr.) | 12795.16 | 7617.77 | 5940.17 | 7173.15 | 5726.36 |
| EV / Net Operating Revenue (X) | 9.88 | 7.60 | 7.37 | 8.82 | 6.88 |
| EV / EBITDA (X) | 58.36 | 39.84 | 58.85 | 48.37 | 42.83 |
| MarketCap / Net Operating Revenue (X) | 10.27 | 8.09 | 7.93 | 9.25 | 7.19 |
| Retention Ratios (%) | 75.23 | 79.85 | 91.88 | 94.64 | 96.53 |
| Price / BV (X) | 18.68 | 13.79 | 12.49 | 16.50 | 16.41 |
| Price / Net Operating Revenue (X) | 10.27 | 8.09 | 7.93 | 9.25 | 7.19 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Astrazeneca Pharma India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 64.60. This value is within the healthy range. It has increased from 39.70 (Mar 23) to 64.60, marking an increase of 24.90.
- For Diluted EPS (Rs.), as of Mar 24, the value is 64.60. This value is within the healthy range. It has increased from 39.70 (Mar 23) to 64.60, marking an increase of 24.90.
- For Cash EPS (Rs.), as of Mar 24, the value is 70.58. This value is within the healthy range. It has increased from 46.22 (Mar 23) to 70.58, marking an increase of 24.36.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 284.77. It has increased from 235.48 (Mar 23) to 284.77, marking an increase of 49.29.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 284.77. It has increased from 235.48 (Mar 23) to 284.77, marking an increase of 49.29.
- For Dividend / Share (Rs.), as of Mar 24, the value is 24.00. This value exceeds the healthy maximum of 3. It has increased from 16.00 (Mar 23) to 24.00, marking an increase of 8.00.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 518.21. It has increased from 401.19 (Mar 23) to 518.21, marking an increase of 117.02.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 87.70. This value is within the healthy range. It has increased from 76.49 (Mar 23) to 87.70, marking an increase of 11.21.
- For PBIT / Share (Rs.), as of Mar 24, the value is 81.72. This value is within the healthy range. It has increased from 69.98 (Mar 23) to 81.72, marking an increase of 11.74.
- For PBT / Share (Rs.), as of Mar 24, the value is 87.82. This value is within the healthy range. It has increased from 53.64 (Mar 23) to 87.82, marking an increase of 34.18.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 64.60. This value is within the healthy range. It has increased from 39.72 (Mar 23) to 64.60, marking an increase of 24.88.
- For PBDIT Margin (%), as of Mar 24, the value is 16.92. This value is within the healthy range. It has decreased from 19.06 (Mar 23) to 16.92, marking a decrease of 2.14.
- For PBIT Margin (%), as of Mar 24, the value is 15.77. This value is within the healthy range. It has decreased from 17.44 (Mar 23) to 15.77, marking a decrease of 1.67.
- For PBT Margin (%), as of Mar 24, the value is 16.94. This value is within the healthy range. It has increased from 13.37 (Mar 23) to 16.94, marking an increase of 3.57.
- For Net Profit Margin (%), as of Mar 24, the value is 12.46. This value exceeds the healthy maximum of 10. It has increased from 9.89 (Mar 23) to 12.46, marking an increase of 2.57.
- For Return on Networth / Equity (%), as of Mar 24, the value is 22.68. This value is within the healthy range. It has increased from 16.86 (Mar 23) to 22.68, marking an increase of 5.82.
- For Return on Capital Employeed (%), as of Mar 24, the value is 28.34. This value is within the healthy range. It has decreased from 29.11 (Mar 23) to 28.34, marking a decrease of 0.77.
- For Return On Assets (%), as of Mar 24, the value is 14.98. This value is within the healthy range. It has increased from 10.08 (Mar 23) to 14.98, marking an increase of 4.90.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 1.26. It has increased from 1.09 (Mar 23) to 1.26, marking an increase of 0.17.
- For Current Ratio (X), as of Mar 24, the value is 2.61. This value is within the healthy range. It has increased from 2.18 (Mar 23) to 2.61, marking an increase of 0.43.
- For Quick Ratio (X), as of Mar 24, the value is 1.97. This value is within the healthy range. It has increased from 1.68 (Mar 23) to 1.97, marking an increase of 0.29.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.61. This value is below the healthy minimum of 4. It has increased from 0.51 (Mar 23) to 0.61, marking an increase of 0.10.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 24.76. This value is within the healthy range. It has increased from 20.14 (Mar 23) to 24.76, marking an increase of 4.62.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 22.66. This value is within the healthy range. It has increased from 17.30 (Mar 23) to 22.66, marking an increase of 5.36.
- For Earning Retention Ratio (%), as of Mar 24, the value is 75.24. This value exceeds the healthy maximum of 70. It has decreased from 79.86 (Mar 23) to 75.24, marking a decrease of 4.62.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 77.34. This value exceeds the healthy maximum of 70. It has decreased from 82.70 (Mar 23) to 77.34, marking a decrease of 5.36.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 182.71. This value is within the healthy range. It has decreased from 303.52 (Mar 23) to 182.71, marking a decrease of 120.81.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 121.90. This value is within the healthy range. It has decreased from 222.46 (Mar 23) to 121.90, marking a decrease of 100.56.
- For Enterprise Value (Cr.), as of Mar 24, the value is 12,795.16. It has increased from 7,617.77 (Mar 23) to 12,795.16, marking an increase of 5,177.39.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 9.88. This value exceeds the healthy maximum of 3. It has increased from 7.60 (Mar 23) to 9.88, marking an increase of 2.28.
- For EV / EBITDA (X), as of Mar 24, the value is 58.36. This value exceeds the healthy maximum of 15. It has increased from 39.84 (Mar 23) to 58.36, marking an increase of 18.52.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 10.27. This value exceeds the healthy maximum of 3. It has increased from 8.09 (Mar 23) to 10.27, marking an increase of 2.18.
- For Retention Ratios (%), as of Mar 24, the value is 75.23. This value exceeds the healthy maximum of 70. It has decreased from 79.85 (Mar 23) to 75.23, marking a decrease of 4.62.
- For Price / BV (X), as of Mar 24, the value is 18.68. This value exceeds the healthy maximum of 3. It has increased from 13.79 (Mar 23) to 18.68, marking an increase of 4.89.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 10.27. This value exceeds the healthy maximum of 3. It has increased from 8.09 (Mar 23) to 10.27, marking an increase of 2.18.
- For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astrazeneca Pharma India Ltd:
- Net Profit Margin: 12.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 28.34% (Industry Average ROCE: 16%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 22.68% (Industry Average ROE: 16.32%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 121.9
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.97
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 111 (Industry average Stock P/E: 42.42)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.46%
About the Company - Qualitative Analysis
AstraZeneca Pharma India Ltd. is a Public Limited Listed company incorporated on 11/07/1979 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is L24231KA1979PLC003563 and registration number is 003563. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1295.53 Cr. and Equity Capital is Rs. 5.00 Cr. for the Year ended 31/03/2024.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Block N1, 12th Floor, Bengaluru Karnataka 560045 | comp.secy@astrazeneca.com http://www.astrazeneca.com/india |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Narayan K Seshadri | Chairperson & Independent Director |
| Mr. Sanjeev Kumar Panchal | Executive Director |
| Ms. Bhavana Agrawal | Executive Director |
| Ms. Sylvia Lorena Varela Ramon | Non Executive Director |
| Ms. Hooi Bien Chuah | Non Executive Director |
| Ms. Shilpa Divekar Nirula | Independent Director |
| Ms. Revathy Ashok | Independent Director |
FAQ
What is the latest intrinsic value of Astrazeneca Pharma India Ltd?
The latest intrinsic value of Astrazeneca Pharma India Ltd as on 12 March 2025 is ₹5548.87, which is 25.70% lower than the current market price of 7,468.00, indicating the stock is overvalued by 25.70%. The intrinsic value of Astrazeneca Pharma India Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹18,670 Cr. and recorded a high/low of ₹8,140/4,050 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹674 Cr and total liabilities of ₹1,241 Cr.
What is the Market Cap of Astrazeneca Pharma India Ltd?
The Market Cap of Astrazeneca Pharma India Ltd is 18,670 Cr..
What is the current Stock Price of Astrazeneca Pharma India Ltd as on 12 March 2025?
The current stock price of Astrazeneca Pharma India Ltd as on 12 March 2025 is ₹7,468.
What is the High / Low of Astrazeneca Pharma India Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of Astrazeneca Pharma India Ltd stocks is ₹8,140/4,050.
What is the Stock P/E of Astrazeneca Pharma India Ltd?
The Stock P/E of Astrazeneca Pharma India Ltd is 111.
What is the Book Value of Astrazeneca Pharma India Ltd?
The Book Value of Astrazeneca Pharma India Ltd is 272.
What is the Dividend Yield of Astrazeneca Pharma India Ltd?
The Dividend Yield of Astrazeneca Pharma India Ltd is 0.32 %.
What is the ROCE of Astrazeneca Pharma India Ltd?
The ROCE of Astrazeneca Pharma India Ltd is 31.1 %.
What is the ROE of Astrazeneca Pharma India Ltd?
The ROE of Astrazeneca Pharma India Ltd is 22.9 %.
What is the Face Value of Astrazeneca Pharma India Ltd?
The Face Value of Astrazeneca Pharma India Ltd is 2.00.